An experimental acne drug just failed two key clinical trials -- and the stock's getting obliterated

  • Dermatology biotech Dermira said on Monday that its experimental drug to treat acne failed two key clinical trials.
  • Dermira was studying the drug in kids over 9 years old to see if it could reduce the number of inflammatory and non-inflammatory lesions on that person’s skin compared to a control arm.
  • Dermira, which had a market cap of about $US1 billion when markets closed on Friday was down as much as 64% on Monday in pre-market trading.
  • “We are surprised and extremely disappointed by the results of the Phase 3 program,” Dermira CEO Tom Wiggans said in a news release.
  • The company is also developing treatments for hyperhidrosis, otherwise known as excessive sweating, and atopic dermatitis.

Screen Shot 2018 03 05 at 8.42.21 AMMarkets Insider

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at